Believe in possibilities

BUILDING BETTER BIOLOGICS™

We believe we have a unique opportunity to use our combined talents to achieve something bigger than ourselves.

Together, we can shape new possibilities for patients everywhere.

Zymeworks Scientists in Lab

Zymeworks Inc. is a publicly listed (NYSE: ZYME), clinical-stage, biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer.

Zymeworks’ suite of complementary therapeutic platforms and its fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated product candidates.

Zymeworks’ lead product candidate, ZW25, is a HER2-targeted bispecific antibody developed using Zymeworks proprietary Azymetric™ platform. ZW25 is currently being evaluated in global Phase 1 and Phase 2 clinical trials as a best-in-class treatment for patients with HER2-expressing cancers, including biliary tract, gastroesophageal adenocarcinomas, breast, and other tumor types. Zymeworks’ second candidate, ZW49, is a HER2-targeted antibody drug conjugate (ADC) developed using Zymeworks’ proprietary Azymetric™ and ZymeLink™ platforms. ZW49 is currently being evaluated in a Phase 1 clinical trial as a treatment for patients with HER2-expressing cancers.

Zymeworks is also advancing a deep pipeline of preclinical product candidates and discovery-stage programs in oncology (including immuno-oncology agents) and other therapeutic areas. In addition to Zymeworks’ wholly owned pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies.

Zymeworks Group Photo

Leadership

Ali Tehrani PhD
President & CEO
Ali Tehrani PhD
President & CEO

Dr. Tehrani is one of our co-founders and has served as our President and Chief Executive Officer and as a member of our Board of Directors since the Company’s inception in September 2003. He has been an integral part of many of our corporate achievements including raising seed and angel financing and overseeing our technical operations and patent filings. Dr. Tehrani holds both Bachelor’s and Master’s of Science degrees in Biochemistry from the University of Massachusetts, and has a Doctoral degree in Microbiology and Immunology from the University of British Columbia. While completing his Ph.D. degree he co-founded the Student Biotechnology Network, for which he received the UBC Faculty of Science Achievement Award for Outstanding Leadership in 2002. Dr. Tehrani has served as a board director for the Student Biotechnology Network, CQDM, LifeSciences British Columbia, on the MITACS Industrial Advisory Board, and on BIOTECanada’s Industrial and Environmental Committee. He was a Council Member on British Columbia’s Premier’s Technology Council from 2016 to 2018. Currently, he is a member of the board of directors of Creatus Biosciences Inc.

Neil Klompas
EVP, Business Operations & CFO
Neil Klompas
EVP, Business Operations & CFO
Mr. Klompas joined Zymeworks in March 2007 and currently serves as our Executive Vice President, Business Operations and Chief Financial Officer. Prior to joining Zymeworks, he worked with KPMG LLP in Canada and the United States, most recently (from 2005 to 2007) with KPMG’s Pharmaceuticals, Biotechnology and Medical Device M&A Transaction Services practice in Princeton, New Jersey, where he advised on transactions including mergers, acquisitions, divestitures and strategic alliances. Prior to that, from 2000 to 2005 Mr. Klompas worked with KPMG’s Canadian Biotechnology and Pharmaceuticals practice. Mr. Klompas currently serves on the Board of Liminal BioSciences Inc. (NASDAQ & TSX:LMNL). Mr. Klompas is a Chartered Professional Accountant and is a member of Chartered Professional Accountants of British Columbia. Mr. Klompas also holds a degree in Microbiology & Immunology from the University of British Columbia. He serves on the faculty advisory board for Biotechnology and Chemistry for Camosun College and as a member of the board of directors of Ovensa Inc., a private biotechnology company.
Diana Hausman MD
CMO
Diana Hausman MD
CMO
Dr. Hausman has served as our Chief Medical Officer since June 2016. She is a board certified medical oncologist and brings more than 18 years of clinical drug development experience to our management team. Prior to joining Zymeworks, she was Chief Medical Officer at Oncothyreon Inc. from January 2012 to April 2016, where she oversaw the clinical program for their lead Phase 2 targeted anti-HER2 cancer therapy. While there, Dr. Hausman also led planning for the clinical development of a therapeutic vaccine, and earlier served as the company’s Vice President, Clinical Development from September 2009 to December 2011. She has also held positions at ZymoGenetics, Inc., Berlex, Inc. and Immunex Corporation, working across multiple indications, including oncology, hematology, hepatitis C and autoimmune disease. Dr. Hausman received her internal medicine training and specialty training in hematology and medical oncology at the University of Washington. She holds an M.D. degree from the University of Pennsylvania and an A.B. in biology from Princeton University.
Tony Polverino PhD
EVP, Early Development & CSO
Tony Polverino PhD
EVP, Early Development & CSO

Dr. Polverino joined Zymeworks in September 2018 and currently serves as our Executive Vice President, Early Development and Chief Scientific Officer. Prior to joining Zymeworks, from 2015 until 2018, Dr. Polverino was at Kite Pharma, Inc., which was acquired by Gilead Sciences, Inc. in 2017. While at Kite, he served as the interim Chief Scientific Officer and, before that, as Vice President of Research. During his tenure, Yescarta®, Kite’s lead chimeric antigen receptor (CAR)-T cell therapy, was approved for relapsed or refractory B cell lymphoma, and multiple programs were advanced to the clinic. Dr. Polverino also assembled an innovative chimeric antigen receptor discovery and development team. Prior to Kite, he was at Amgen Inc. from 1994 to 2014, serving in a number of research leadership roles of increasing responsibility. While at Amgen he managed and advanced numerous research programs utilizing multiple therapeutic modalities, including immunotherapy, oncolytic viruses, bispecific antibodies, antibody-drug conjugates, and small molecules. He also played a key role in the development of over 12 novel antigens for antibody therapeutics. Dr. Polverino has served as a member of the board of directors of BrainStorm Cell Therapeutics Inc. since February 2018. Dr. Polverino earned his undergraduate degree in pharmacology from Adelaide University and his Ph.D. in biochemistry from Flinders University, both in Adelaide, Australia.

Kathryn O'Driscoll
Chief People Officer
Kathryn O'Driscoll
Chief People Officer

Ms. O’Driscoll joined Zymeworks in October 2019 and currently serves as Chief People Officer. She brings a wealth of experience in the software and global health sectors. Prior to joining Zymeworks, she held a variety of Human Resource leadership positions for Microsoft and served as Chief Human Resources Officer for PATH, a global organization working to accelerate health equity. Most recently, she served as VP of People for Snowflake, the data warehouse built for the cloud, located in San Mateo, California. Ms. O’Driscoll recently served on the Board of Social Venture Partners as part of her long and continuing engagement with that organization. She invests time and resources to support organizations working toward equity and inclusion. She is a graduate of Pacific University in Oregon.

John Babcook
SVP, Discovery Research
John Babcook
SVP, Discovery Research
Mr. Babcook has served as our Senior Vice President, Discovery Research since March 2016 and is responsible for target, antibody, and drug conjugate discovery and associated partnerships. For over 20 years, Mr. Babcook has made significant contributions to the international biopharmaceutical industry. In 1998, Mr. Babcook co-founded ImmGenics Pharmaceuticals Inc. based on a novel antibody generation platform. In 2000, ImmGenics was acquired by Abgenix Inc., which was subsequently acquired by Amgen, Inc. in 2006. Mr. Babcook led the Canadian research team at ImmGenics (and Abgenix and Amgen, respectively) from 1998 to 2010. Mr. Babcook went on to establish the Biologics Division at the Centre for Drug Research and Development, where he served as Vice President, Biologics from September 2010 to March 2016, in addition to becoming the founding President and Chief Scientific Officer of Kairos Therapeutics Inc. in January 2015. While at Kairos, he was responsible for the development of its ADC platform and therapeutic pipeline and also formed multiple collaborations, including the strategic partnership and the merger with Zymeworks in March 2016. Mr. Babcook has participated in the development of more than 100 therapeutic antibody-based programs, several of which are now in the clinic, including two that have been approved by the FDA for treatment. Mr. Babcook has served as an Adjunct Professor in Molecular Biology and Biochemistry at Simon Fraser University. He is the recipient of an Honorary Doctorate recipient from the British Columbia Institute of Technology and the recipient of the LifeSciences British Columbia’s “Innovation and Achievement” Award. In 2019, Zymeworks was awarded the Hanson Wade World ADC award for Best ADC Platform Technology, a platform Mr. Babcook was instrumental in creating.
Mark Hollywood
SVP, Technical & Manufacturing Operations
Mark Hollywood
SVP, Technical & Manufacturing Operations
Mr. Hollywood joined Zymeworks in March 2019 as our Senior Vice President, Technical and Manufacturing Operations. Mr. Hollywood brings 25 years of experience in the biopharmaceutical industry, most recently as Vice President and Head of ZymoGenetics, Inc. (a Bristol-Myers Squibb company), where he led outsourced manufacturing and supply chain operations and was responsible for building a multi-host biological drug substance manufacturing facility. He joined ZymoGenetics in 2010 and led technical and manufacturing operations for a portfolio of development and commercial stage assets. Mr. Hollywood brings a wealth of experience in technical operations management, having held positions of increasing responsibility in process development, manufacturing, quality and regulatory compliance at biotech/pharmaceutical organizations including Centeon LLC, Amgen Inc., Dendreon Corporation and CellCyte Genetics Corporation. Mr. Hollywood has a Bachelor of Science degree in Biological Sciences from Western Illinois University.
Surjit Dixit PhD
VP, Technology
Surjit Dixit PhD
VP, Technology

Dr. Dixit has held various roles at Zymeworks since joining the Company in July 2007, and currently serves as our Vice President, Technology. Dr. Dixit is responsible for the advancement of our various proprietary technology platforms, including ZymeCAD, Azymetric and AlbuCORE. Prior to joining Zymeworks, Dr. Dixit was the coordinator of Computational Molecular Biophysics at Wesleyan University, Connecticut from January 2005 to July 2007, where he was instrumental in the development of novel methods for management and mining of high throughput molecular dynamics simulation data. Dr. Dixit obtained his Ph.D. at the Indian Institute of Technology, New Delhi, researching methods for computing the binding and interaction energies in protein DNA complexes. Subsequently, from October 1999 to February 2001 he was a postdoctoral research associate at the Université Henri Poincaré, Nancy, France, working on the development and implementation of highly accurate methods for the prediction of binding energies in drug discovery research.

Bruce Hart PhD
VP, Regulatory
Bruce Hart PhD
VP, Regulatory
Dr. Hart joined Zymeworks in January 2019 as our Vice President, Regulatory Affairs. Dr. Hart brings over 20 years of regulatory affairs experience including 15 years at Seattle Genetics where he led the buildout of the regulatory affairs group and was the regulatory lead for ADCETRIS® through its lifecycle from pre-IND to BLA approval. His group also advanced multiple programs to the clinic during his tenure. Prior to Seattle Genetics, he was at Schering-Plough and was a contractor for the National Cancer Institute and National Library of Medicine. Dr. Hart earned his undergraduate degree in biochemistry from the University of Texas in Austin and his Ph.D. in pharmacology and toxicology from the University of Kansas in Lawrence.



Darren Hoegler
VP, Finance
Darren Hoegler
VP, Finance
Mr. Hoegler joined Zymeworks in October 2019 as Vice President, Finance to lead the company’s growing financial reporting, treasury, financial planning, tax and clinical finance functions. Mr. Hoegler brings over 20 years of diverse financial management and leadership experience to Zymeworks from executive and senior management roles in the aerospace and defense, shipping and biotechnology industries. Prior to joining Zymeworks, Mr. Hoegler spent twelve years at MacDonald, Dettwiler and Associates (now Maxar Technologies), a leading global provider of advanced space-based technology solutions, primarily as Vice President, Corporate Controller and Chief Accounting Officer where he led the company’s global financial reporting and financial planning functions. Mr. Hoegler also previously held financial leadership roles at Canadian based shipping and biotechnology companies and in the audit practice at KPMG in their Vancouver, Canada; Melbourne, Australia; and Oslo, Norway offices. Mr. Hoegler is a Chartered Professional Accountant and is a member of the Chartered Professional Accountants of British Columbia. Mr. Hoegler earned a Bachelor of Commerce degree (with honours) from the University of British Columbia.
Neil Josephson MD
VP, Clinical Research
Neil Josephson MD
VP, Clinical Research

Dr. Josephson joined Zymeworks in April 2019 as our Vice President of Clinical Research. Prior to joining Zymeworks he was a Vice President in Clinical Development at Seattle Genetics where he worked on multiple early and late stage programs from 2013-2019, including leading the frontline approval of ADCETRIS® in Hodgkin Lymphoma. From 2002-2013 Dr. Josephson was a full time faculty member of the Division of Hematology at the University of Washington and the Puget Sound Blood Center, serving as an Associate Professor of Medicine and the Director of Hemophilia Care Program. He completed fellowship training in Hematology and Oncology at the University of Washington and holds an M.D. degree from Columbia University and an A.B. in biology from Dartmouth College.

Jennifer Kaufman-Shaw PhD, LLB
VP, Intellectual Property
Jennifer Kaufman-Shaw PhD, LLB
VP, Intellectual Property
Dr. Kaufman-Shaw joined Zymeworks in August 2014 and currently serves as our Vice President, Intellectual Property. Dr. Kaufman-Shaw brings with her over 25 years of intellectual property management, strategy and execution experience to the management team. Dr. Kaufman-Shaw is responsible for our intellectual property portfolio and global patent strategy, as well as supporting our therapeutics and platform licensing activities. Prior to joining Zymeworks, Dr. Kaufman-Shaw was a Co-Founder of ImStar Therapeutics Inc., a biotechnology company, and also served as its Vice President, Intellectual Property and Legal Affairs from its founding in May 2012 to July 2014. She also served as a Vice President at the biotechnology company Sirius Genomics Inc. (from August 2007 to May 2012), and held various senior roles at QLT Inc. (from July 1997 to July 2007) including, most recently, Vice President, Patent Counsel (from 2005 to 2007), where she was responsible for developing and executing intellectual property strategies. Dr. Kaufman-Shaw is admitted to the Alberta Bar and holds a Bachelor of Laws (LL.B.) and a doctorate in Biochemistry from the University of Alberta.
David Poon PhD
VP, Business Development & Alliance Management
David Poon PhD
VP, Business Development & Alliance Management
Dr. Poon has held various scientific and corporate roles at Zymeworks since joining in October 2007, and currently serves as our Vice President, Business Development and Alliance Management. Dr. Poon is responsible for establishing strategic licensing partnerships and collaborations with multinationals and academic institutions, competitive intelligence and alliance management. While at Zymeworks, Dr. Poon has been instrumental in establishing the majority of our pharma partnerships. He also made key scientific contributions to the development of the Azymetric™ and EFECT™ therapeutic platforms, which are being deployed in a number of Zymeworks’ internal and partnered therapeutic programs. Dr. Poon obtained his Ph.D. in Chemistry at the University of British Columbia.
Steven Xanthoudakis PhD
VP, Global Search & External Scientific Strategy
Steven Xanthoudakis PhD
VP, Global Search & External Scientific Strategy

Dr. Steven Xanthoudakis joined Zymeworks in September 2019 and currently serves as the Vice President of Global Search and External Scientific Strategy. Dr. Xanthoudakis brings over 27 years of pharmaceutical industry experience, holding various positions at Merck in discovery research, in external partnering, and as Research Investigator in the Department of Neurogenetics at Hoffman La Roche (NJ, USA). He also served as the Chief Business Development Officer for the Quebec Consortium for Drug Discovery (CQDM) where he managed the execution of numerous R&D deals involving pharma, biotech, and academia. Dr. Xanthoudakis continues to participate as a member of the Research Management Committee of BioCanRx and Glyconet. He received a doctoral degree from the Department of Microbiology and Immunology at McGill University.

Board of Directors

Lota Zoth
Chairman of the Board
Lota Zoth
Chairman of the Board

Ms. Zoth has served as the Chair of the Board of Directors since September 2019 and has served as a member of our Board of Directors since November 2016. Ms. Zoth is a Certified Public Accountant and has served as Chief Financial Officer, Chief Accounting Officer and Controller for various publicly traded companies, including MedImmune, Inc. and PSINet, Inc., and as a financial executive in various roles at Sodexho Marriott, Marriott International, Pepsi-Cola International and PepsiCo. Ms. Zoth began her career as an auditor with Ernst & Young. Ms. Zoth serves on the boards and audit committees of Nasdaq-listed biopharmaceutical companies (Inovio Pharmaceuticals, Inc., and NewLink Genetics Corporation). Previously, Ms. Zoth served on the boards of six other biopharmaceutical companies (Aeras, Circassia Pharmaceuticals, plc, Hyperion Therapeutics, Inc., Ikaria, Inc. Orexigen Therapeutics, Inc., and Spark Therapeutics, Inc.).

Troy Cox
Director
Troy Cox
Director

Troy Cox served as Chief Executive Officer of Foundation Medicine, Inc. (“Foundation Medicine”) from February 2017 through February 2019 as CEO and member of the Board of Directors from February 2017 until July 2018, and in the additional role of President of Foundation Medicine from February 2018 until July 2018. Prior to Foundation Medicine, Mr. Cox served as Senior Vice President, Sales & Marketing at Genentech, Inc. (“Genentech”) from February 2010 until February 2017. Before joining Genentech, Mr. Cox served as President of CNS operations at UCB S.A. (“UCB BioPharma”) with responsibility for developing and commercializing therapeutics for diseases primarily related to the central nervous system. Prior to UCB BioPharma, Mr. Cox held senior commercial leadership roles with Sanofi-Aventis and Schering-Plough. Mr. Cox received a B.B.A. in finance from the University of Kentucky and an M.B.A. from the University of Missouri.

Kenneth Hillan MB, CHB
Director
Kenneth Hillan MB, CHB
Director
Dr. Hillan has served as a member of our Board of Directors since February 2017. Dr. Hillan is currently Head of Therapeutics at 23andMe. Dr. Hillan has served on the board of directors of Achaogen, Inc., a public biopharmaceutical company, since October 2011. Dr. Hillan served as Achaogen’s President and President, R&D from January 2018 to October 2018, as its Chief Executive Officer from October 2011 until December 2017, and as its Chief Medical Officer from April 2011 to July 2014. Prior to joining Achaogen, Dr. Hillan worked at Genentech, Inc., a pharmaceutical company and a member of the Roche Group, from August 1994 to March 2011. Dr. Hillan held progressively senior roles at Genentech, most recently holding the position of Senior Vice President & Head of Roche Product Development, Asia Pacific from April 2010 to March 2011, and was responsible for numerous successful drug approvals and led the medical and scientific strategies for Genentech’s immunology, tissue growth and repair drug portfolio. Dr. Hillan also served on the board of directors of Relypsa, Inc., a publicly traded biotechnology company that was acquired in September 2016 by Galencia AG for $1.5 billion, from June 2014 to September 2016. Dr. Hillan has an M.B. and a Ch.B. (Bachelor of Medicine and Surgery) degree from the Faculty of Medicine at the University of Glasgow in the United Kingdom. Dr. Hillan is a Fellow of the Royal College of Surgeons, and a Fellow of the Royal College of Pathologists.
Sue Mahony
Director
Sue Mahony
Director

Dr. Sue Mahony is an executive with over 30 years of experience in pharmaceutical and life sciences companies. Dr. Mahony served as Senior Vice President of Eli Lilly and Company and President of Lilly Oncology from February 2011 until August 2018. She joined Lilly in 2000, holding senior leadership positions in product development, marketing, human resources, and general management. Prior to joining Lilly, Dr. Mahony served in sales and marketing roles in Europe for over a decade for Schering-Plough, Amgen, and Bristol-Myers Squibb. Dr. Mahony has served on the Board of Directors of Assembly Biosciences, Inc. since December 2017 and on the Board of Directors for Vifor Pharma since May 2019. Dr. Mahony received a B.Sc. and a Ph.D. from Aston University and an M.B.A. from London Business School.

Hollings C Renton
Director
Hollings C Renton
Director
Mr. Renton has served as a member of our Board of Directors since February 2017. Mr. Renton served as CEO and President of Onyx Pharmaceuticals, Inc. from March 1993 to March 2008 and was the chair of the board of directors of Onyx from June 2000 to March 2008. Onyx was acquired by Amgen Inc. in 2013 for $10.4 billion. Before joining Onyx, Mr. Renton was the President and Chief Operating Officer of Chiron Corporation, a pharmaceutical company, from December 1991 to December 1993. Mr. Renton served in a variety of executive roles at Cetus Corporation from 1983, including as President from 1990 to 1991, Chief Operating Officer from 1987 to 1990 and Chief Financial Officer from 1983 to 1987, prior to its acquisition by Chiron in 1991. Mr. Renton serves as chair of the board of directors of Portola Pharmaceuticals Inc., where he has been a board member since March 2010. He has also served on the board of directors of AnaptysBio, Inc. since June 2015. Previously, Mr. Renton served on the boards of three biopharmaceutical companies, KYTHERA Biopharmaceuticals, Inc. (December 2014 to October 2015), Affymax, Inc. (June 2009 to November 2014) and Rigel Pharmaceuticals, Inc. (January 2004 to March 2014). Mr. Renton also previously served on the board of Cepheid Inc., a molecular diagnostics company, from March 2000 to November 2016. Mr. Renton received his M.B.A. from the University of Michigan and his B.S. in Mathematics from Colorado State University.
Natalie Sacks MD
Director
Natalie Sacks MD
Director

Dr. Sacks has served as a member of our Board of Directors since August 2017. Dr. Sacks is a trained oncologist, and has served as the Chief Medical Officer of Harpoon Therapeutics, Inc. since October 2018 and on the board of directors of Caribou Biosciences, Inc., a genome editing company, since May 2018. Prior to joining Harpoon, Dr. Sacks served as Chief Medical Officer of Aduro Biotech and as an advisor on development strategy for multiple firms. Previously, she was Vice President of Clinical Development at Onyx Pharmaceuticals (acquired by Amgen) from 2011 to 2014, where she played a key role in the development and approval of Kyprolis®, an FDA-approved therapy for the treatment of multiple myeloma, and in business development strategy. Prior to that, she served as Vice President of Clinical Research for Exelixis where she directed the development of a portfolio of small molecules, with responsibilities ranging from IND filings to late-stage development, including late-stage development of Cometriq™, an FDA-approved therapy for the treatment of medullary thyroid cancer. Earlier in her career, Dr. Sacks served as Vice President of Clinical Development at Cell Genesys, a company focused on the development of cancer vaccines and engineered chimeric antigen receptor (CAR) T cell. In addition to her industry experience, Dr. Sacks held an active faculty appointment at the University of California, San Francisco, as an assistant clinical professor of medicine in the Division of Hematology/Oncology from 2003 to 2016. She received her M.D. from the University of Pennsylvania School of Medicine, her M.S. in Biostatistics from Harvard University School of Public Health and her B.A. in Mathematics from Bryn Mawr College.

Ali Tehrani PhD
Director
Ali Tehrani PhD
Director
Dr. Tehrani is one of our co-founders and has served as our President and Chief Executive Officer and as a member of our Board of Directors since the Company’s inception in September 2003. He has been an integral part of many of our corporate achievements including raising seed and angel financing and overseeing our technical operations and patent filings. Dr. Tehrani holds both Bachelor’s and Master’s of Science degrees in Biochemistry from the University of Massachusetts, and has a Doctoral degree in Microbiology and Immunology from the University of British Columbia. While completing his Ph.D. degree he co-founded the Student Biotechnology Network, for which he received the UBC Faculty of Science Achievement Award for Outstanding Leadership in 2002. Dr. Tehrani has served as a board director for the Student Biotechnology Network, CQDM, LifeSciences British Columbia, on the MITACS Industrial Advisory Board, and on BIOTECanada’s Industrial and Environmental Committee. He was a Council Member on British Columbia’s Premier’s Technology Council from 2016 to 2018. Currently, he is a member of the board of directors of Creatus Biosciences Inc.